Ardelyx, Inc. (ARDX): Total Assets
$501.60M
As of 2025-12-31
$575.89M
As of 2026-06-30
+38.2%
3-year compound annual growth
+20.0%
5-year compound annual growth
+15.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $501.60M | +15.1% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $435.75M | +46.4% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $297.58M | +56.6% | 2025-02-20, Balance as of period end |
| 2022-12-31 | $190.07M | +26.8% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $149.91M | -25.6% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $201.56M | -22.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $259.78M | +41.7% | 2021-03-08, Balance as of period end |
| 2018-12-31 | $183.33M | +16.1% | 2020-03-06, Balance as of period end |
| 2017-12-31 | $157.90M | -25.9% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $213.13M | +82.2% | 2018-03-14, Balance as of period end |
| 2015-12-31 | $116.95M | +3.1% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $113.41M | +164.3% | 2016-03-04, Balance as of period end |
| 2013-12-31 | $42.90M | n/a | 2015-03-05, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.64B | +25.7% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $8.54B | -30.8% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $432.97M | +24.1% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $1.17B | -1.1% |
| MannKind Corp (MNKD) | 2025-12-31 | $792.18M | +101.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $605.19M | +1.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $936.02M | +1.8% |
Compare ARDX, INVA, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗